Teva Pharmaceutical Industries Total Non-Operating Income/Expense 2010-2024 | TEVA

Teva Pharmaceutical Industries annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
  • Teva Pharmaceutical Industries total non-operating income/expense for the quarter ending September 30, 2024 was $-0.272B, a 2.86% decline year-over-year.
  • Teva Pharmaceutical Industries total non-operating income/expense for the twelve months ending September 30, 2024 was $-1.012B, a 3.89% decline year-over-year.
  • Teva Pharmaceutical Industries annual total non-operating income/expense for 2023 was $-1.057B, a 9.42% increase from 2022.
  • Teva Pharmaceutical Industries annual total non-operating income/expense for 2022 was $-0.966B, a 8.7% decline from 2021.
  • Teva Pharmaceutical Industries annual total non-operating income/expense for 2021 was $-1.058B, a 26.86% increase from 2020.
Teva Pharmaceutical Industries Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $-1,057
2022 $-966
2021 $-1,058
2020 $-834
2019 $-822
2018 $-3,986
2017 $-895
2016 $-1,330
2015 $-1,000
2014 $-963
2013 $-1,187
2012 $-1,645
2011 $-583
2010 $-225
2009 $-202
Teva Pharmaceutical Industries Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-09-30 $-272
2024-06-30 $-241
2024-03-31 $-250
2023-12-31 $-249
2023-09-30 $-280
2023-06-30 $-268
2023-03-31 $-260
2022-12-31 $-245
2022-09-30 $-252
2022-06-30 $-211
2022-03-31 $-258
2021-12-31 $-232
2021-09-30 $-262
2021-06-30 $-274
2021-03-31 $-290
2020-12-31 $4,358
2020-09-30 $-4,745
2020-06-30 $-223
2020-03-31 $-224
2019-12-31 $-187
2019-09-30 $-211
2019-06-30 $-206
2019-03-31 $-218
2018-12-31 $-3,130
2018-09-30 $-229
2018-06-30 $-356
2018-03-31 $-271
2017-12-31 $-191
2017-09-30 $-259
2017-06-30 $-238
2017-03-31 $-207
2016-12-31 $-356
2016-09-30 $260
2016-06-30 $-817
2016-03-31 $-417
2015-12-31 $898
2015-09-30 $-1,081
2015-06-30 $-326
2015-03-31 $-491
2014-12-31 $-356
2014-09-30 $-248
2014-06-30 $-221
2014-03-31 $-138
2013-12-31 $-519
2013-09-30 $-242
2013-06-30 $-193
2013-03-31 $-233
2012-12-31 $-1,405
2012-09-30 $-73
2012-06-30 $-97
2012-03-31 $-70
2011-12-31 $-498
2011-09-30 $-67
2011-06-30 $20
2011-03-31 $-38
2010-12-31 $-47
2010-09-30 $-3
2010-06-30 $-148
2010-03-31 $-27
2009-12-31 $137
2009-09-30 $-149
2009-06-30 $-113
2009-03-31 $-77
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.395B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00